GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (CHIX:MOLNz) » Definitions » ROE % Adjusted to Book Value

Molecular Partners AG (CHIX:MOLNZ) ROE % Adjusted to Book Value : -45.03% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG ROE % Adjusted to Book Value?

Molecular Partners AG's ROE % for the quarter that ended in Sep. 2024 was -44.58%. Molecular Partners AG's PB Ratio for the quarter that ended in Sep. 2024 was 0.99. Molecular Partners AG's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -45.03%.


Molecular Partners AG ROE % Adjusted to Book Value Historical Data

The historical data trend for Molecular Partners AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG ROE % Adjusted to Book Value Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.84 -13.41 -11.22 73.22 -45.64

Molecular Partners AG Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.11 -64.33 -36.99 -26.98 -45.03

Competitive Comparison of Molecular Partners AG's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Molecular Partners AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's ROE % Adjusted to Book Value falls into.



Molecular Partners AG ROE % Adjusted to Book Value Calculation

Molecular Partners AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-30.12% / 0.66
=-45.64%

Molecular Partners AG's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-44.58% / 0.99
=-45.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Partners AG ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG Headlines

No Headlines